Related Experiment Videos
Benefits of beta-blockers in heart failure
O I Sleiman1, J Murin, W M Ghanem
11st Department of Internal Medicine, University Hospital, Faculty of Medicine, Comenius University, Bratislava, Slovakia. Ossamasleiman@hotmail.com
Insights
Beta-blockers are now recommended for heart failure (HF) patients, yet they remain underused. This study highlights their benefits and investigates reasons for low prescription rates in HF care.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure (HF) management has evolved significantly.
- Beta-blockers, once contraindicated, are now preferred HF treatments.
- Emphasis on beta-blocker benefits is crucial for wider clinical application.
Purpose of the Study:
- To review the proven benefits of beta-blockers in heart failure patients.
- To provide practical guidance on beta-blocker use in HF.
- To assess the current underuse of beta-blockers in HF and explore reasons.
Main Methods:
- Retrospective analysis of heart failure patient records.
- Data collected from the 1st Internal Department, University Hospital in Bratislava (Jan-Dec 1997).
- Evaluation of beta-blocker prescription frequency.
Main Results:
- Only 20% (30 out of 150) of admitted HF patients received beta-blockers.
- Significant underutilization of beta-blockers in HF patients was observed.
- Despite evidence, beta-blockers are not universally prescribed.
Conclusions:
- Beta-blockers should be used in all HF patients with reduced ejection fraction unless contraindicated.
- Current clinical practice shows a concerning underuse of beta-blockers in heart failure.
- Further efforts are needed to promote appropriate beta-blocker therapy in HF management.
Abstract:
The problem of heart failure (HF) has become a topic of great interest. Until recently, the use of beta-blockers in patients with HF was considered as a contraindication. Times have changed and the contraindicated drug is now an advised and preferred one to be used in HF patients with certain advised recommendations for its use in a safe and beneficial way. Still we need to emphasize the benefits of these agents in order to achieve more application in HF patients. Here we try to stress the proved beneficial effects of beta-blockers by major studies in HF patients, and to supply the reader with practical information regarding the use of these agents with a look at the frequency of using them and the possible reasons behind their underuse. The files of heart failure patients admitted to 1st Internal Department in the University Hospital in Bratislava in the period between January and December 1997 were checked to show the magnitude of using beta-blockers in them. Among 150 patients admitted during the above mentioned period only 30 patients (20%) received beta-blockers. It seems that beta-blockers have to be used in all patients with HF with reduced ejection fraction unless a real contraindication exists, but the actual data shows that beta-blockers are still underused. (Tab. 2, Ref. 30.)